ImmunoGen, Inc. Announces Presentations at Upcoming 2008 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--May 23, 2008--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that new clinical data will be reported at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting with three targeted anticancer compounds in development by the Company and its collaborators. The ASCO annual meeting will be held May 30 to June 3, 2008 in Chicago, IL.
"We're looking forward to an exciting ASCO meeting this year and to the presentation of new findings with both our IMGN242 anticancer agent and two compounds in development through our collaborations," commented Mitchel Sayare, Chairman and CEO. "We're pleased with the progress being made as we - and our partners - work to achieve significant new treatments for cancer."
Posters on the following clinical-stage compounds will be presented:
IMGN242
"The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors" (abstract # 3066).
-- Poster Session: Sunday, June 1, 2008 from 2:00 PM - 6:00 PM (CDT).
-- IMGN242 is wholly owned by ImmunoGen and comprises the Company's DM4 cell-killing agent attached to its CanAg-binding antibody, huC242.
AVE1642
"A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumors (ST)" (abstract #3582).
-- Poster Session: Sunday, June 1, 2008 from 2:00 PM - 6:00 PM (CDT).
-- AVE1642, a naked (non-conjugated) antibody, was licensed by ImmunoGen to sanofi-aventis as part of a broader collaboration between the companies.
Trastuzumab-DM1 (T-DM1)
"A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)" (abstract #1028).
"A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC)" (abstract #1029).
-- Poster Session (for both): Tuesday, June 3, 2008 from 8:00 AM to 12:00 noon (CDT).
-- T-DM1 comprises ImmunoGen's DM1 cell-killing agent linked to Genentech's HER2-targeting antibody, trastuzumab.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - IMGN901 and IMGN242. Three TAP compounds are in clinical testing through ImmunoGen's collaborations with other companies - T-DM1 in development by Genentech, and AVE9633 and SAR3419, in development by sanofi-aventis. Additionally, the naked antibody compound, AVE1642, is in clinical testing through the Company's collaboration with sanofi-aventis. Multiple compounds are in research/preclinical development through ImmunoGen's collaborations and internal programs.
CONTACT: Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
Media:
KMorrisPR
Kathryn Morris, 845-635-9828
Kathryn@kmorrispr.com
